Rockville, MD-based LabGenomics USA, a subsidiary of LabGenomics in South Korea, added its fourth U.S. laboratory facility certified under the Clinical Laboratory Improvement Amendments (CLIA) with the completed acquisition of Integrated Molecular Diagnostics (IMD)'s labs.
IMD's molecular diagnostics program serves oncology programs in community-based hospitals, the company's CEO Israel Villasenor said in a related news release. IMD operates two CLIA laboratories, one in Sacramento, CA, and another in Aurora, CO. The Colorado-based facility, an academic-level esoteric center of excellence, is located on the Anschutz Medical Campus at the University of Colorado, according to IMD's website.
In August 2023, LabGenomics acquired New Jersey-based QDx Pathology in a move to expand LabGenomics' into the North American market. The company has a strategic vision to acquire clinical laboratory companies across the U.S., Canada, and South America, according to the company's Lab.g USA website.
LabGenomics specializes in molecular and genetic diagnostics, including genetic screening and next-generation sequencing oncology testing. The company has said its aim is to consolidate its acquired laboratories into a cohesive network, as well as develop and manufacture advanced laboratory developed test (LDT) kits.
IMD has collaborated with Cedars-Sinai Molecular Lab on a next-generation sequencing (NGS) cancer panel for solid tumors, with plans to launch it as an LDT, the company said.
